Roivant Sciences ROIV Insider Ownership

NASDAQ ROIV

$40.55 -0.12 (-0.30%)

As of: Nov 10, 2026 · 12:12 PM EST

Insider Holdings by Owner

381.45Mn Shares

Pharma Technologies Ltd. Dexcel102.85Mn27.0%

Investments (Uk) Ltd Svf73.03Mn19.1%

Chemical Co., Ltd. Sumitomo71.25Mn18.7%

Vivek Ramaswamy33.65Mn8.8%

Mayukh Sukhatme18.56Mn4.9%

Other insiders (16)82.11Mn21.5%

Insider Ownership Statistics

as of 30 Sep, 2026

Insider Ownership

18.61%

▼-0.025% pp QoQ

Shares Held by Insiders

134.47Mn

filed for Sep 2026

▼-0.13% QoQ

Shares Outstanding

722.67Mn

722,668,062 shares

Direct Holdings

95.47Mn

Indirect: 39.01Mn

Net Open-Market Trades

-1.63Mn

net sold · -$59.19Mn in Sep 2026

Insiders Holding Shares

with Form 4 holdings on file

Shares Owned by Insiders

Shares held % of outstanding

Latest —

Average ownership —

Peak ownership —

Open-Market Insider Trades

Bought Sold

Latest quarter —

Net over range —

Net-buying quarters —

Insider Ownership Summary

Updated Nov 4, 2026

Over the past year, ROIV insiders sold $597.26 million of stock (23.03Mn shares) on the open market and bought none.

Roivant Sciences' open-market sales in the past 12 months came from 11 insiders; no insider bought.
QVT Financial LP was the top open-market seller of Roivant Sciences over the past 12 months, with $147.38 million sold (5.66Mn shares) and the latest sale on June 30, 2026.
The latest open-market trade on record is a sale of 200K shares for $7.32 million by Eric Venker (President & Immunovant CEO) on October 28, 2026.
Outside the open market, Roivant Sciences insiders received 278.3K shares in stock awards, acquired 23.34Mn shares through option exercises and conversions, gave up 1.21Mn shares to cover taxes or exercise prices and gave away 110.49K shares as gifts over the past 12 months.
Business Quant data puts insider holdings in ROIV at 134.02Mn shares across insiders' latest Form 4 filings, down 0.47% from 134.65Mn shares at the end of Q2 2026.
Indirect holdings, through trusts, partnerships, family members and other entities, make up 29.11% (39.01Mn shares) of Roivant Sciences' insider total, with the other 70.89% (95.01Mn shares) held directly.
ROIV's insider total is spread across 14 insiders who have filed a Form 4 in the past two years.
ROIV's three largest insider shareholders, per their latest Form 4 filings, are Vivek Ramaswamy (10% owner, 47.01Mn shares), Daniel Allen Gold (Director, 20.93Mn shares) and Mayukh Sukhatme (President & CIO, 18.56Mn shares).
Vivek Ramaswamy holds 35.08% of the combined insider position in Roivant Sciences.
Institutions held 77.05% of Roivant Sciences' outstanding shares in their Q2 2026 13F filings, insiders about 18.55% based on their latest Form 4 filings, and other investors, including the public, the remaining 4.40%.
Over the past 12 months, 14 insiders reported transactions in Roivant Sciences stock in 98 Form 4 filings.
The insider data for ROIV reflects Form 4 filings through October 30, 2026.

Form 4 Holdings

Insiders Holding ROIV

Insiders 21

Shares held 381.45Mn

Of outstanding 52.78%

#	Insider	Position	Direct	Indirect	Total	Share of Insiders	Last Filed
1	Pharma Technologies Ltd. Dexcel	TenPercentOwner	102,849,443	0	102,849,443	27.0%	14 Nov, 2022
2	Investments (Uk) Ltd Svf	TenPercentOwner	0	73,031,667	73,031,667	19.1%	02 Oct, 2023
3	Chemical Co., Ltd. Sumitomo	TenPercentOwner	0	71,251,083	71,251,083	18.7%	26 Jun, 2023
4	Vivek Ramaswamy	TenPercentOwner	33,653,755	0	33,653,755	8.8%	15 Dec, 2025
5	Mayukh Sukhatme	President Cio	18,563,884	0	18,563,884	4.9%	20 Oct, 2026
6	Matthew Gline	Ceo	16,549,136	0	16,549,136	4.3%	20 Oct, 2026
7	Financial Lp Qvt	Other	0	13,689,166	13,689,166	3.6%	30 Jun, 2026
8	Frank Torti	President And Vant Chair	13,495,893	0	13,495,893	3.5%	02 Oct, 2026
9	Global Investors Lp Viking	TenPercentOwner	0	12,884,307	12,884,307	3.4%	26 Jun, 2023
10	Global Performance Llc Viking	TenPercentOwner	0	12,884,307	12,884,307	3.4%	26 Jun, 2023
11	Daniel Allen Gold	Director	8,965,815	0	8,965,815	2.4%	18 Sep, 2026
12	Keith S Manchester	Director	1,753,457	0	1,753,457	0.5%	18 Sep, 2026
13	Eric Venker	President Immunovant Ceo	999,154	0	999,154	0.3%	05 Nov, 2026
14	Richard Pulik	Cfo	269,681	0	269,681	0.1%	22 Sep, 2026
15	Rakhi Kumar	Chief Accounting Officer	162,306	0	162,306	0.0%	24 Feb, 2025
16	Ilan Oren	Director	124,490	0	124,490	0.0%	27 Oct, 2026
17	James C Momtazee	Director	112,265	0	112,265	0.0%	27 Oct, 2026
18	Jennifer Humes	Chief Accounting Officer	106,419	0	106,419	0.0%	22 Sep, 2026
19	Andrew Lo	Director	52,142	0	52,142	0.0%	19 Sep, 2022
20	Meghan Fitzgerald	Director	41,162	0	41,162	0.0%	18 Sep, 2026
21	Melissa B, Epperly	Director	15,351	0	15,351	0.0%	27 Oct, 2026

Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.

Form 4 Filings

1,019 Insider Transactions

Source SEC Form 4

Latest quarter Sep 2026

Date	Insider	Position	Transaction	Shares	Price	Value	Shares Held After	Ownership
03 Nov, 2026	Eric Venker	President Immunovant Ceo	Disposed S	200,000	$36.31	$7.26Mn	999,154	Direct
28 Oct, 2026	Eric Venker	President Immunovant Ceo	Disposed S	200,000	$36.59	$7.32Mn	1,199,154	Direct
23 Oct, 2026	Ilan Oren	Director	Acquired A	810	$0.00	$0	124,490	Direct
23 Oct, 2026	James C Momtazee	Director	Acquired A	383	$0.00	$0	112,342	Direct
23 Oct, 2026	Melissa B, Epperly	Director	Acquired A	513	$0.00	$0	15,467	Direct
23 Oct, 2026	James C Momtazee	Director	Disposed F	77	$36.49	$2.81K	112,265	Direct
23 Oct, 2026	Melissa B, Epperly	Director	Disposed F	116	$36.49	$4.23K	15,351	Direct
20 Oct, 2026	Eric Venker	President Immunovant Ceo	Disposed S	185,856	$35.09	$6.52Mn	1,413,298	Direct
20 Oct, 2026	Eric Venker	President Immunovant Ceo	Disposed S	14,144	$35.42	$500.98K	1,399,154	Direct
16 Oct, 2026	Matthew Gline	Ceo	Disposed F	34,638	$33.53	$1.16Mn	16,549,136	Direct
16 Oct, 2026	Mayukh Sukhatme	President Cio	Disposed F	19,976	$33.53	$669.80K	18,563,884	Direct
01 Oct, 2026	Melissa B, Epperly	Director	Acquired M	17,750	$4.46	$79.17K	32,704	Direct
01 Oct, 2026	Melissa B, Epperly	Director	Disposed S	16,850	$36.08	$607.95K	15,854	Direct
01 Oct, 2026	Melissa B, Epperly	Director	Disposed S	900	$36.57	$32.91K	14,954	Direct
01 Oct, 2026	Melissa B, Epperly	Director	Disposed M	17,750	$0.00	$0	151,416	Direct
30 Sep, 2026	Matthew Gline	Ceo	Disposed F	76,171	$36.57	$2.79Mn	16,583,774	Direct
30 Sep, 2026	Mayukh Sukhatme	President Cio	Disposed F	46,879	$36.57	$1.71Mn	18,583,860	Direct
30 Sep, 2026	Frank Torti	President And Vant Chair	Acquired F	40,309	$36.57	$1.47Mn	13,495,893	Direct
30 Sep, 2026	Eric Venker	President Immunovant Ceo	Acquired M	200,000	$3.85	$770.00K	1,799,154	Direct
30 Sep, 2026	Eric Venker	President Immunovant Ceo	Disposed S	200,000	$36.62	$7.32Mn	1,599,154	Direct

Showing 1 to 20 of 1,019 transactions